Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuroscientific Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)
Latest News
Healthcare Shares
Here are the 5 best performing ASX biotech shares of 2021
Healthcare Shares
Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Share Gainers
Neuroscientific Biopharmaceuticals (ASX:NSB) share price leaps 11% on study update
Share Market News
Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt
Healthcare Shares
NeuroScientific Biopharmaceuticals (ASX:NSB) share price wobbles on study results
Share Market News
This ASX biotech share is up 20% today
Share Market News
Why this ASX microcap skyrocketed 190% on Tuesday
NSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Neuroscientific Biopharmaceuticals Ltd
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.
NSB Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Mar 2024 | $0.05 | $0.00 | 0.00% | 45,808 | $0.05 | $0.05 | $0.05 |
27 Mar 2024 | $0.05 | $0.00 | 0.00% | 823,104 | $0.05 | $0.05 | $0.05 |
26 Mar 2024 | $0.05 | $0.00 | 0.00% | 461,209 | $0.05 | $0.05 | $0.04 |
25 Mar 2024 | $0.05 | $0.00 | 0.00% | 831,250 | $0.05 | $0.05 | $0.05 |
22 Mar 2024 | $0.05 | $0.00 | 0.00% | 196,266 | $0.05 | $0.05 | $0.05 |
21 Mar 2024 | $0.05 | $0.00 | 0.00% | 175,958 | $0.05 | $0.05 | $0.05 |
20 Mar 2024 | $0.05 | $0.00 | 0.00% | 542,729 | $0.05 | $0.05 | $0.05 |
18 Mar 2024 | $0.05 | $0.00 | 0.00% | 41,179 | $0.05 | $0.05 | $0.05 |
15 Mar 2024 | $0.05 | $0.00 | 0.00% | 69,762 | $0.05 | $0.05 | $0.05 |
14 Mar 2024 | $0.05 | $0.00 | 0.00% | 331,304 | $0.05 | $0.05 | $0.05 |
13 Mar 2024 | $0.05 | $0.00 | 0.00% | 299,067 | $0.05 | $0.05 | $0.05 |
12 Mar 2024 | $0.05 | $0.01 | 23.26% | 1,287,338 | $0.04 | $0.05 | $0.04 |
11 Mar 2024 | $0.04 | $0.00 | 0.00% | 523,871 | $0.04 | $0.04 | $0.04 |
08 Mar 2024 | $0.04 | $0.00 | 0.00% | 344,643 | $0.04 | $0.05 | $0.04 |
07 Mar 2024 | $0.04 | $0.00 | 0.00% | 98,502 | $0.04 | $0.05 | $0.04 |
06 Mar 2024 | $0.04 | $0.00 | 0.00% | 124,997 | $0.04 | $0.04 | $0.04 |
05 Mar 2024 | $0.05 | $0.00 | 0.00% | 13,222 | $0.05 | $0.05 | $0.05 |
04 Mar 2024 | $0.04 | $0.00 | 0.00% | 246,425 | $0.05 | $0.05 | $0.04 |
01 Mar 2024 | $0.05 | $0.00 | 0.00% | 1,060,440 | $0.05 | $0.05 | $0.05 |
29 Feb 2024 | $0.05 | $0.01 | 27.03% | 4,408,923 | $0.04 | $0.06 | $0.04 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
04 Jul 2023 | Stephen Quantrill | Buy | 180,000 | $17,375 |
On-market trade.
|
01 Jun 2023 | Paul Rennie | Buy | 240,134 | $23,989 |
On-market trade.
|
24 May 2023 | Paul Rennie | Buy | 229,651 | $22,378 |
On-market trade.
|
22 May 2023 | Anton Uvarov | Buy | 49,405 | $5,188 |
On-market trade.
|
18 May 2023 | Anton Uvarov | Buy | 275,595 | $23,188 |
On-market trade.
|
17 May 2023 | Paul Rennie | Buy | 320,968 | $26,710 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Anton Uvarov | Non-Executive Director | Nov 2022 |
Dr Uvarov has experience as an equity analyst in the healthcare industry with a focus on the biotechnology sector, both domestically and internationally. Prior to moving to Australia, he was with Citigroup Global Markets where he spent two years as a member of a New York based biotechnology team that has been continuously ranked top 4 for Biotechnology in the All-America Institutional Investor survey. Dr Uvarov's scientific expertise and company knowledge spreads across a variety of therapeutic areas and spectrum of market capitalizations with his particular interest in early-stage biotechnology companies.
|
Mr Christopher Ntoumenopoulos | Non-Executive DirectorNon-Executive Chairman | Nov 2023 |
--
|
Dr Anthony (Tony) Keating | Non-Executive Director | Dec 2023 |
Dr Keating is co-founded and led ResApp Health , Tony was a Vice President at Pfizer. Prior to co-founding ResApp, Tony was Director,Commercial Engagement at UniQuest where he led commercialisation of science-based technologies which included identification, development and funding of opportunities as well as sourcing and negotiating transactions with investors and strategic partners.
|
Mr Clarke Barlow | Non-Executive Director | Nov 2023 |
--
|
Dr Linda Friedland | Non-Executive Director | Oct 2023 |
Dr Friedland with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial insitutions. Linda is a non-executive director on several Healthcare boards within Australia and abroad. Among her roles, Dr Friedland is Deputy Chairman of the Neurological Council of Western Australia (NCWA), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder and director of FFD Capital LLC (USA) and Asia- Pacific partner for Camelot BioCapital. An author of seven healthcare-related bestsellers with a career in television and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries
|
Mr Christopher (Chris) Bryan Achurch | Company Secretary | Feb 2024 |
-
|
Christopher (Chris) Bryan Achurch | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Mcrae Technology Pty Ltd | 19,122,262 | 13.22% |
Bnp Paribas Noms Pty Ltd <Drp> | 18,460,425 | 12.77% |
Mcrae Investments Pty Ltd | 6,133,000 | 4.24% |
Utas Holdings Pty Ltd | 3,954,123 | 2.73% |
Citicorp Nominees Pty Limited | 2,844,785 | 1.97% |
Ecu Holdings Pty Ltd | 2,555,556 | 1.77% |
Trevor Borrows Investment Pty Ltd | 2,250,000 | 1.56% |
Mr Edward Joseph & Mrs Margaret Mary Gettingby | 2,090,000 | 1.45% |
Hsbc Custody Nominees (Australia) Limited | 2,003,712 | 1.39% |
Ms Yulia Uvarova | 2,000,000 | 1.38% |
Gcn Investments Pty Ltd | 2,000,000 | 1.38% |
Whale Watch Holdings Limited | 1,927,341 | 1.33% |
Mr Edward Joseph & Mrs Margaret Mary Gettingby (i) | 1,703,333 | 1.18% |
Solequest Pty Ltd | 1,691,422 | 1.17% |
Dossman Pty Ltd | 1,595,666 | 1.10% |
Ice Lake Investments Pty Ltd | 1,550,000 | 1.07% |
Mr Paul John Rennie | 1,090,753 | 0.75% |
Yodambao Pty Ltd | 1,041,667 | 0.72% |
Wilk Holdings Pty Limited | 1,000,000 | 0.69% |
Tastool Pty Limited | 1,000,000 | 0.69% |
Valorem Capital Pty Ltd | 1,000,000 | 0.69% |